Spero Therapeutics

Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.

Spero Therapeutics headquartered in United States, North America, operates in the Biotechnology, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $79.8B in funding across 180 round(s). With a team of 11-50 employees, Spero Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Spero Therapeutics, raised $3.0M. Discover more about their projects, partnerships, and impact on our platform.